RxSight/$RXST
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About RxSight
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
Ticker
$RXST
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
498
ISIN
US78349D1072
Website
RxSight Metrics
BasicAdvanced
$515M
-
-$0.67
1.29
-
Price and volume
Market cap
$515M
Beta
1.29
52-week high
$60.81
52-week low
$12.53
Average daily volume
747K
Financial strength
Current ratio
12.683
Quick ratio
11.446
Long term debt to equity
3.934
Total debt to equity
4.311
Interest coverage (TTM)
-1,755.33%
Profitability
EBITDA (TTM)
-33.626
Gross margin (TTM)
71.87%
Net profit margin (TTM)
-17.90%
Operating margin (TTM)
-24.85%
Effective tax rate (TTM)
-0.22%
Revenue per employee (TTM)
$300,000
Management effectiveness
Return on assets (TTM)
-9.29%
Return on equity (TTM)
-11.98%
Valuation
Price to revenue (TTM)
3.399
Price to book
1.84
Price to tangible book (TTM)
1.84
Price to free cash flow (TTM)
-24.568
Free cash flow yield (TTM)
-4.07%
Free cash flow per share (TTM)
-51.57%
Growth
Revenue change (TTM)
46.70%
Earnings per share change (TTM)
-46.38%
3-year revenue growth (CAGR)
74.21%
3-year earnings per share growth (CAGR)
-39.77%
What the Analysts think about RxSight
Analyst ratings (Buy, Hold, Sell) for RxSight stock.
RxSight Financial Performance
Revenues and expenses
RxSight Earnings Performance
Company profitability
RxSight News
AllArticlesVideos
RxSight, Inc. to Participate in the Stifel 2025 Virtual Ophthalmology Forum
GlobeNewsWire·1 month ago
RxSight, Inc. to Present at the Bank of America Healthcare Conference
GlobeNewsWire·2 months ago
RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for RxSight stock?
RxSight (RXST) has a market cap of $515M as of June 30, 2025.
What is the P/E ratio for RxSight stock?
The price to earnings (P/E) ratio for RxSight (RXST) stock is 0 as of June 30, 2025.
Does RxSight stock pay dividends?
No, RxSight (RXST) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next RxSight dividend payment date?
RxSight (RXST) stock does not pay dividends to its shareholders.
What is the beta indicator for RxSight?
RxSight (RXST) has a beta rating of 1.29. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.